Opportunity Information: Apply for RFA CA 12 013
Apply for RFA CA 12 013
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "NCI National Clinical Trials Network Network Lead Academic Participating Sites (U10)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Jul 23, 2012 and posted on Jul 23, 2012.
- Applicants must submit their applications by Jan 15, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $21,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "NCI National Clinical Trials Network - Network Lead Academic Participating Sites (U10)" (Funding Opportunity Number RFA-CA-12-013) is a National Institutes of Health cooperative agreement designed to support institutions that will serve as key clinical trial-performing hubs within the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). The central purpose is to strengthen and coordinate the capacity to run high-quality, state-of-the-art cancer clinical trials across multiple institutions, with a particular emphasis on large, definitive studies that evaluate new cancer therapies and related clinical approaches for both adult and pediatric patients. In addition to treatment trials, the FOA highlights advanced imaging clinical trials, reflecting NCI's interest in modern imaging methods as part of cancer research and clinical decision-making.
This award uses the cooperative agreement mechanism (U10), which generally indicates an active partnership between the awardee and the federal sponsor. In practice, that means funded sites are not just receiving funds to operate independently; they are expected to work closely with NCI and the broader NCTN structure, follow network standards, and contribute to shared network goals such as consistent trial conduct, reliable data collection, and multi-site collaboration. The overall aim is to enable complex, multi-institutional trials to be launched and completed efficiently and to ensure that results are robust enough to influence clinical practice.
The NCTN is described as having six coordinated components, each supported through its own separate funding opportunity announcement. Those components are: (1) Network Group Operations Centers, (2) Network Group Statistics and Data Management Centers, (3) Network Group Integrated Translational Science Centers, (4) Lead Academic Participating Site Centers (the focus of this FOA), (5) Network Radiotherapy and Imaging Core Services Centers, and (6) a Canadian Collaborating Clinical Trials Network. This structure signals that the Lead Academic Participating Sites are one part of a larger ecosystem, where operations, statistics/data management, translational science, and specialized imaging/radiotherapy services are organized as complementary functions. The Lead Academic Participating Site role is therefore positioned as the on-the-ground clinical engine that enrolls participants, implements protocols, and contributes to network-wide trial execution, while interfacing with the other components that provide centralized support and oversight.
From an administrative and eligibility standpoint, the opportunity is categorized as discretionary funding and falls under NIH activity areas related to education and health, specifically CFDA numbers 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research). The FOA states there is no cost sharing or matching requirement. The estimated total funding amount listed is $21,000,000, reflecting a substantial investment in building and sustaining the participating site infrastructure required to carry out national-scale cancer trials.
Eligible applicants include a wide range of U.S.-based organizations: public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with or without 501(c)(3) status (as long as they are not higher education institutions in the specified category), and for-profit organizations (excluding small businesses, based on the eligibility line as presented). The eligibility section also explicitly includes certain institution types and community-focused organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and regional organizations. At the same time, the FOA clearly excludes non-U.S. entities from applying, including foreign institutions and non-domestic components of U.S. organizations, and it does not allow foreign components as defined by NIH policy. This underscores that the funded Lead Academic Participating Sites are intended to be U.S.-based anchors for NCTN trial activity.
Key dates show the announcement was posted and created on July 23, 2012, with an original and current closing date of January 15, 2013, and an archive date of February 15, 2013. While those dates indicate the specific announcement is historical and no longer accepting applications, the description still provides a clear picture of how NCI intended to organize and resource the participating site layer of the NCTN during that funding cycle.
For applicants at the time, the practical takeaway would have been that NCI was seeking institutions capable of functioning as high-performing lead academic trial sites within a national network environment, prepared to conduct advanced, multi-institution cancer clinical trials at scale, coordinate with specialized network centers (operations, statistics/data management, translational science, imaging/radiotherapy cores), and adhere to network-wide expectations for quality, collaboration, and trial efficiency. The full announcement and detailed requirements were provided through the NIH grants page linked in the posting (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-013.html), and technical access issues were directed to the NIH Office of Extramural Research (OER) webmaster contact.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "NCI National Clinical Trials Network - Network Lead Academic Participating Sites (U10)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-CA-12-013.
Which federal agency is offering this opportunity?
This is a National Institutes of Health (NIH) cooperative agreement opportunity associated with the National Cancer Institute (NCI).
What is the purpose of this opportunity?
The central purpose is to support institutions that will serve as key clinical trial-performing hubs within the NCI National Clinical Trials Network (NCTN), strengthening and coordinating the capacity to run high-quality, state-of-the-art cancer clinical trials across multiple institutions.
What kind of studies is this program focused on?
The emphasis is on large, definitive cancer clinical trials that evaluate new cancer therapies and related clinical approaches, including trials for both adult and pediatric patients. The FOA also highlights advanced imaging clinical trials as part of NCI's interest in modern imaging methods in cancer research and clinical decision-making.
What does it mean that this is a cooperative agreement (U10)?
The U10 mechanism indicates an active partnership between the awardee and the federal sponsor. Funded sites are expected to work closely with NCI and the broader NCTN structure, follow network standards, and contribute to shared network goals such as consistent trial conduct, reliable data collection, and multi-site collaboration.
What is the National Clinical Trials Network (NCTN) in this context?
The NCTN is described as a coordinated national structure designed to enable complex, multi-institutional cancer trials to be launched and completed efficiently, with results robust enough to influence clinical practice.
Where do Lead Academic Participating Sites fit within the NCTN structure?
Lead Academic Participating Site Centers are one of six coordinated NCTN components. Their role is positioned as the on-the-ground clinical engine that enrolls participants, implements protocols, and contributes to network-wide trial execution while interfacing with other network components that provide centralized support and oversight.
What are the six coordinated NCTN components mentioned in the FOA?
The FOA describes six components, each supported through separate funding opportunity announcements:
- Network Group Operations Centers
- Network Group Statistics and Data Management Centers
- Network Group Integrated Translational Science Centers
- Lead Academic Participating Site Centers (the focus of this FOA)
- Network Radiotherapy and Imaging Core Services Centers
- A Canadian Collaborating Clinical Trials Network
What is the primary role of a Lead Academic Participating Site under this FOA?
Based on the description provided, the Lead Academic Participating Site role is to function as a high-performing clinical trial site within a national network environment by enrolling participants, implementing protocols, supporting high-quality trial conduct, and collaborating across multiple institutions in alignment with NCTN standards and network-wide goals.
Is this opportunity considered discretionary funding?
Yes. The opportunity is categorized as discretionary funding.
Which NIH activity areas or CFDA numbers are associated with this opportunity?
The FOA falls under NIH activity areas related to education and health and lists the following CFDA numbers:
- 93.394 - Cancer Detection and Diagnosis Research
- 93.395 - Cancer Treatment Research
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
How much total funding is estimated for this opportunity?
The estimated total funding amount listed is $21,000,000.
Who is eligible to apply?
Eligible applicants include a range of U.S.-based organizations, including:
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Nonprofits with or without 501(c)(3) status (as described in the eligibility text provided)
- For-profit organizations (excluding small businesses, based on the eligibility line as presented)
Are minority-serving institutions and certain community-focused institutions included as eligible applicants?
Yes. The eligibility section explicitly includes institution types and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and regional organizations.
Are non-U.S. organizations eligible to apply?
No. The FOA excludes non-U.S. entities from applying, including foreign institutions and non-domestic components of U.S. organizations, and it does not allow foreign components as defined by NIH policy.
Does the FOA allow foreign components as part of an application?
No. The FOA indicates that foreign components are not allowed as defined by NIH policy.
When was this announcement posted and created?
The announcement was posted and created on July 23, 2012.
What were the closing date and archive date for this FOA?
The original and current closing date listed is January 15, 2013, and the archive date is February 15, 2013.
Is this FOA still accepting applications?
No. The dates provided indicate this specific announcement is historical and is no longer accepting applications.
Where was the full FOA posted?
The full announcement and detailed requirements were provided through the NIH grants page at: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-013.html
What kinds of expectations are implied for funded sites?
The description indicates funded sites are expected to operate within the NCTN framework, collaborate closely with NCI and other NCTN components, follow network standards, and contribute to shared goals such as consistent trial conduct, reliable data collection, and efficient multi-site trial execution.
What should someone do if they had technical access issues with the posting?
The posting notes that technical access issues were directed to the NIH Office of Extramural Research (OER) webmaster contact.
Browse more opportunities from the same category: Education Health
Next opportunity: ACES and Ecosystem Markets Conference
Previous opportunity: NCI National Clinical Trials Network Network Group Integrated Translational Science Centers (U10)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 12 013
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 12 013) also looked into and applied for these:
| Funding Opportunity |
|---|
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 12 251 Funding Number: PAR 12 251 Agency: National Institutes of Health Category: Education Health Funding Amount: $75,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 12 023 Funding Number: RFA CA 12 023 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R01) Apply for RFA DA 13 010 Funding Number: RFA DA 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R21) Apply for RFA DA 13 011 Funding Number: RFA DA 13 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Examination of Survivorship Care Planning Efficacy and Impact R21 Apply for PA 12 274 Funding Number: PA 12 274 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Examination of Survivorship Care Planning Efficacy and Impact R01 Apply for PA 12 275 Funding Number: PA 12 275 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY 2013 American Schools and Hospitals Abroad Program Apply for DRAFT APS ASHA 12 000001 Funding Number: DRAFT APS ASHA 12 000001 Agency: Agency for International Development Category: Education Health Funding Amount: $2,000,000 |
| HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21) Apply for PA 12 280 Funding Number: PA 12 280 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01) Apply for PA 12 281 Funding Number: PA 12 281 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS Science Track Award for Research Transition (R03) Apply for PA 12 282 Funding Number: PA 12 282 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Revisions for Early Stage Development of Informatics Technology (R01) Apply for PAR 12 286 Funding Number: PAR 12 286 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Advanced Development of Informatics Technology (U24) Apply for PAR 12 287 Funding Number: PAR 12 287 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Early Stage Development of Informatics Technology (U01) Apply for PAR 12 288 Funding Number: PAR 12 288 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Revisions for Early Stage Development of Informatics Technology (U01) Apply for PAR 12 289 Funding Number: PAR 12 289 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions for Early Stage Development of Informatics Technology (P01) Apply for PAR 12 290 Funding Number: PAR 12 290 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Research Answers to NCIs Provocative Questions Group A (R01) Apply for RFA CA 12 015 Funding Number: RFA CA 12 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group A (R21) Apply for RFA CA 12 016 Funding Number: RFA CA 12 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group B (R01) Apply for RFA CA 12 017 Funding Number: RFA CA 12 017 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Answers to NCIs Provocative Questions Group B (R21) Apply for RFA CA 12 018 Funding Number: RFA CA 12 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions Group C (R01) Apply for RFA CA 12 019 Funding Number: RFA CA 12 019 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 12 013", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.